Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Vertex Pharmaceuticals (VRTX) is trading at its highest price since late March with shares up 14% in mid-afternoon trading after competitor Galapagos NV (GLPG) released mediocre mid-stage test results for its new cystic fibrosis drug Friday.

Shares for the Boston-based Vertex rose $20.78 -- 14.1% -- to $168.49 on the news that Galapagos' FEV-1 improvements in its Phase II trial came in below Wall Street's expectations. Galapagos, meanwhile, fell $4.29 -- 4.48% -- $91.52 in mid-afternoon trading as the company also announced that its possible collaboration with AbbVie Inc. (ABBV) on a different triple combination therapy seems to no longer be in the works after AbbVie walked away from the project, Galapagos said in a press release.

Galapagos' FEV-1 improvements for its CF drug came in at 3.4%, which was under analysts' estimates of 5%. Sweat chloride levels were reported to decrease in patients compared to the placebo at 19.6 mmol/L but that figure still pales in comparison to Vertex's figures of approximately 30-40 mmol/L for its own CF drug.

Vertex, considered the leader in cystic fibrosis treatment, will remain the "dominant [cystic fibrosis] player for the foreseeable future," Brian Abrahams, an analyst for RBC Capital Markets, said in a note. Galapagos' results showed a small level of improvement in patients, but Abrahams does not think the company will be competitive with Vertex. 

Vertex generates about 87% of its revenue from lower-respiratory biopharmaceuticals, making up about 9% of sales of the industry, according to FactSet data.

Abrahams, who covers both companies, lowered his price target for Galapagos to $94 from $100. He thinks Vertex shares are on track to reach $202, according to the note.

More from Stocks

It's Harvest Season for Tax Losses

It's Harvest Season for Tax Losses

Santa Claus Rally? Machines Render Old Stock Market Adages Worthless

Santa Claus Rally? Machines Render Old Stock Market Adages Worthless

Procter & Gamble Helps Lead Dow Jones After Upgrade From Morgan Stanley

Procter & Gamble Helps Lead Dow Jones After Upgrade From Morgan Stanley

Hey Investors, Don't Let the Bad Times Pollute Your Mind

Hey Investors, Don't Let the Bad Times Pollute Your Mind

Make This Dividend Aristocrat a Staple of Your Portfolio

Make This Dividend Aristocrat a Staple of Your Portfolio